Changes to Articles of Incorporation, Bylaws, or Fiscal Year

Filing Overview

Registrant: Galecto, Inc. (although the request metadata identifies Damora Therapeutics, Inc.; the filing text names Galecto, Inc.)

Form and date: Form 8-K reporting events occurring November 2, 2020; signed November 4, 2020. The filing relates to the consummation of the company’s initial public offering.

Material Corporate Actions

  • The company filed an amended and restated certificate of incorporation with the Delaware Secretary of State in connection with the IPO.
  • The certificate authorizes 300,000,000 shares of common stock.
  • It eliminates references to the company’s previously existing preferred stock.
  • It authorizes 10,000,000 shares of undesignated preferred stock issuable in one or more series by the board of directors.
  • The amended and restated bylaws became effective upon effectiveness of the IPO registration statement.
  • The bylaws eliminate stockholder action by written consent in lieu of a meeting and address special meetings, stockholder proposals, director nominations, and conformity with the amended certificate of incorporation.

Financial Metrics and Liquidity

The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, offering proceeds, share price, or other financial metrics.

Outlook, Risks, and Unusual Items

The filing contains no management guidance, operating outlook, risk discussion, contingencies, or unusual financial items. The principal reported changes are the post-IPO capitalization and governance provisions.

Investor Verification Items

  • Confirm that the filing issuer is Galecto, Inc., not Damora Therapeutics, Inc.
  • Review Exhibits 3.1 and 3.2 for the complete amended and restated certificate of incorporation and bylaws.
  • Verify the IPO terms, including shares issued, offering price, gross and net proceeds, and post-IPO capitalization, in the related registration statement and prospectus.
  • Assess the potential effect of the authorized preferred stock on future dilution, voting rights, or change-of-control transactions.
  • Review subsequent filings for the company’s financial condition, clinical development, liquidity runway, and material risks.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.